Abstract
During the last decades, the advent of biological therapies has revolutionized the management of several immune-mediated inflammatory disorders, as inflammatory bowel diseases, autoimmune arthritis and psoriasis, which significantly impact both quality of life and health care economics. Biological therapies currently available can be divided into two main categories: the tumor necrosis factor-α antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol) and interleukin 12/23 monoclonal antibodies (ustekinumab).
Biologics, reducing TNFα bioavailability or inhibiting proximal regulators of inflammatory cascade, represent an established therapeutic strategy of inflammatory autoimmune diseases, with remarkable efficacy and a safety profile that is extensively examined and monitored.
The biology and the immunological effects of TNFα, IL-12, IL-23 and related signalling pathways are accurately summarized. The dosing regimens, methods of administration, pharmacodynamics profiles, and side effects of the currently licensed TNFα antagonists and IL12/IL23 inhibitor are discussed in detail.
Keywords: Adverse events, immune-mediated inflammatory disease, TNFα inhibitors, TNF biology, Ustekinumab.
Current Drug Safety
Title:Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Volume: 11 Issue: 1
Author(s): E. Molinelli, A. Campanati, G. Ganzetti and A. Offidani
Affiliation:
Keywords: Adverse events, immune-mediated inflammatory disease, TNFα inhibitors, TNF biology, Ustekinumab.
Abstract: During the last decades, the advent of biological therapies has revolutionized the management of several immune-mediated inflammatory disorders, as inflammatory bowel diseases, autoimmune arthritis and psoriasis, which significantly impact both quality of life and health care economics. Biological therapies currently available can be divided into two main categories: the tumor necrosis factor-α antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol) and interleukin 12/23 monoclonal antibodies (ustekinumab).
Biologics, reducing TNFα bioavailability or inhibiting proximal regulators of inflammatory cascade, represent an established therapeutic strategy of inflammatory autoimmune diseases, with remarkable efficacy and a safety profile that is extensively examined and monitored.
The biology and the immunological effects of TNFα, IL-12, IL-23 and related signalling pathways are accurately summarized. The dosing regimens, methods of administration, pharmacodynamics profiles, and side effects of the currently licensed TNFα antagonists and IL12/IL23 inhibitor are discussed in detail.
Export Options
About this article
Cite this article as:
Molinelli E., Campanati A., Ganzetti G. and Offidani A., Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666151014115127
DOI https://dx.doi.org/10.2174/1574886310666151014115127 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Prevalence of the Classical and Non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews Role of C1858T Polymorphism of Lymphoid Tyrosine Phosphatase in Egyptian Children and Adolescents with Type 1 Diabetes
Current Diabetes Reviews Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Current Drug Metabolism Mesenchymal Stromal Cells in Rheumatoid Arthritis: Biological Properties and Clinical Applications
Current Stem Cell Research & Therapy Role of Leptin in the Immune System
Current Immunology Reviews (Discontinued) Therapeutic Utility and Medicinal Chemistry of Cathepsin C Inhibitors
Current Topics in Medicinal Chemistry Autoimmunity and Apoptosis - Therapeutic Implications
Current Medicinal Chemistry Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support
Current Pharmaceutical Design Mesenchymal Stem Cells Induced In Vitro Generated Regulatory-T Cells: Potential Soldiers of Transplantation Biology
Current Biotechnology Vitiligo in Children: A Birds Eye View
Current Pediatric Reviews Multiple Sclerosis Therapy Monitoring Based on Gene Expression
Current Pharmaceutical Design Editorial [Hot Topic: Innate Immunity and Autoimmune Disease (Guest Editors: F. Susan Wong and Li Wen)]
Current Molecular Medicine Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte
Current Drug Targets Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases
Current Gene Therapy Mycobacterium Tuberculosis in New Biologic Era
Current Rheumatology Reviews MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Somatic Genome Variations in Health and Disease
Current Genomics